This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
YU EM., LINVILLE L., ROSENTHAL M., ARAGON-CHING JB. A contemporary review of immune checkpoint inhibitors in advanced clear cell renal cell carcinoma. Vaccines. 2021, 9:919.Search in Google Scholar
BARATA PC., RINI BI. Treatment of renal cell carcinoma: current status and future directions. Ca-Cancer J Clin. 2017, 67:507-24.Search in Google Scholar
DÍAZ-MONTERO C., RINI B. The immunology of renal cell carcinoma. Nat Rev Nephrol. 2020, 16:721-35.Search in Google Scholar
HSIEH JJ., PURDUE MP., SIGNORETTI S., SWANTON C., ALBIGES L., SCHMIDINGER M., et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017, 3:17009.Search in Google Scholar
JENKINS RW., BARBIE DA., FLAHERTY KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018, 118:9-16.Search in Google Scholar
MARIN-ACEVEDO JA., KIMBROUGH EO., LOU Y. Mechanisms of resistance to immune checkpoint inhibitors. J Hematol Oncol. 2021, 14:1-29.Search in Google Scholar
HARGADON KM., JOHNSON CE., WILLIAMS CJ: Immune checkpoint blockade therapy for cancer. an overview of fda-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018, 62:29-39.Search in Google Scholar
SHIRAVAND Y., KHODADADI F., KASHANI SMA., HOSSEINI-FARD SR., HOSSEINI S., SADEGHIRAD H., et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022, 29:3044-60.Search in Google Scholar
LIU X., QIAO L. Hyperprogressive disease in malignant carcinoma with immune checkpoint inhibitor use: a review. Front Nutr. 2022, 9:810472.Search in Google Scholar
ZHAO Z., BIAN J., ZHANG J., ZHANG T., LU X. Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: a systematic review and meta-analysis. Front Oncol. 2022, 12:843707.Search in Google Scholar
HAN XJ., ALU A., XIAO YN., WEI YQ., WEI XW. Hyperprogression: a novel response pattern under immunotherapy. Clin Transl Med.. 2020, 10:e167.Search in Google Scholar
WANG X., WANG F., ZHONG M., YARDEN Y., FU L. The biomarkers of hyperprogressive disease in pd-1/pd-L1 blockage therapy. Mol Cancer. 2020, 19:81.Search in Google Scholar
DENIS M., DURUISSEAUX M., BREVET M., DUMONTET C. How can immune checkpoint inhibitors cause hyperprogression in solid tumors? Front Immunol. 2020, 11:492.Search in Google Scholar
PATEL K., MUKHI H., PATEL A., MEHTA D., CLINTON N., BROWN B., et al. Differentiating pseudoprogression from hyperprogression in patients treated with immunotherapies. Targeted Ther Oncol. 2022, 11:16.Search in Google Scholar
ARASANZ H., ZUAZO M., BOCANEGRA A., CHOCARRO L., BLANCO E., MARTÍNEZ M., et al. Hyperprogressive disease: main features and key controversies. Int J Mol Sci. 2021, 22:3736.Search in Google Scholar
PARK HJ., KIM KW., WON SE., YOON S., CHAE YK., TIRUMANI SH., et al. Definition, incidence, and challenges for assessment of hyperprogressive disease during cancer treatment with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2021, 4:e211136.Search in Google Scholar
CHAMPIAT S., DERCLE L., AMMARI S., MASSARD C., HOLLEBECQUE A., POSTEL-VINAY S., et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res. 2017, 23:1920-8.Search in Google Scholar
FERRARA R., MEZQUITA L., TEXIER M., LAHMAR J., AUDIGIER-VALETTE C., TESSONNIER L., et al. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA Oncol. 2018, 4:1543-52.Search in Google Scholar
KATO S., GOODMAN A., WALAVALKAR V., BARKAUSKAS DA., SHARABI A., KURZROCK R. Hyperprogressors after Immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017, 23:4242-50.Search in Google Scholar
ADASHEK JJ., KATO S., FERRARA R., LO RUSSO G., KURZROCK R. Hyperprogression and immune checkpoint inhibitors: hype or progress? Oncologist. 2020, 25:94-8.Search in Google Scholar
MATOS I., MARTIN-LIBERAL J., GARCÍA-RUIZ A., HIERRO C., OCHOA DE OLZA M., VIAPLANA C., et al. Capturing hyperprogressive disease with immune-checkpoint inhibitors using recist 1.1 criteria.. Clin Cancer Res. 2020, 26:1846-55.Search in Google Scholar
KAS B., TALBOT H., FERRARA R., RICHARD C., LAMARQUE JP., PITRE-CHAMPAGNAT S., et al. Clarification of definitions of hyperprogressive disease during immunotherapy for non-small cell lung cancer. JAMA oncol. 2020, 6:1039-46.Search in Google Scholar
JIA W., GAO Q., HAN A., ZHU H., YU J. The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biol Med. 2019, 16:655.Search in Google Scholar
MA Y., WANG Q., DONG Q., ZHAN L., ZHANG J. How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. Am J Cancer Res. 2019, 9:1546-53.Search in Google Scholar
WANG Y., WANG M., WU HX., XU RH. Advancing to the era of cancer immunotherapy. Cancer Commun (Lond). 2021, 9:803-29.Search in Google Scholar
LIN M., VANNESTE B., YU Q., CHEN Z., PENG J., CAI X. Hyperprogression under immunotherapy: a new form of immunotherapy response?—a narrative literature review. Transl Lung Cancer. 2021, 10:3276-91.Search in Google Scholar
KOCIKOWSKI M., DZIUBEK K., PARYS M. Hyperprogression under immune checkpoint-based immunotherapy–current understanding, the role of pd-1/pd-l1 tumour-intrinsic signalling, future directions and a potential large animal model. Cancers. 2020, 12:804.Search in Google Scholar
KROEGER N., PANTUCK AJ., CONNOR WELLS JC. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies. Eur Urol. 2015, 68:506-15.Search in Google Scholar
STARES M., CHAUHAN V., MOUDGIL-JOSHI J. Initial active surveillance for patients with metastatic renal cell carcinoma: 10 years experience at a regional cancer Centre. Cancer Med.. 2022, 12:5255-64.Search in Google Scholar
LI C., JIANG P., WEI S., XU X., WANG J. Regulatory t cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Molecular cancer. 2020, 19:1-23.Search in Google Scholar
WEI Z., ZHANG Y. Immune cells in hyperprogressive disease under immune checkpoint-based immunotherapy. Cells. 2022, 11:1758.Search in Google Scholar
HAN J., DONG L., WU M., MA F. Dynamic polarization of tumor-associated macrophages and their interaction with intratumoral t cells in an inflamed tumor microenvironment: from mechanistic insights to therapeutic opportunities.. Front Immunol. 2023, 14:2246.Search in Google Scholar
TAY C., QIAN Y., SAKAGUCHI S. Hyper-progressive disease: the potential role and consequences of t-regulatory cells foiling anti-pd-1 cancer immunotherapy. Cancers (Basel). 2020, 12:48.Search in Google Scholar
OHUE Y., NISHIKAWA H. Regulatory t (treg) cells in cancer: can treg cells be a new therapeutic target? Cancer Sci. 2019, 110:2080-9.Search in Google Scholar
FENG Y., YE Z., SONG F., HE Y., LIU J. The role of tams in tumor microenvironment and new research progress. Stem Cells Int. 2022, 2022:5775696.Search in Google Scholar
TOKI MI., SYRIGOS N., SYRIGOS K. Hyperprogressive disease: a distinct pattern of progression to immune checkpoint inhibitors. Int J Cancer. 2020, 149:277-86.Search in Google Scholar
ZAREBA P., PINTHUS JH., RUSSO P. The contemporary role of lymph node dissection in the management of renal cell carcinoma.. Ther Adv Urol. 2018, 10:335-42.Search in Google Scholar
SUN JX., LIU CQ., ZHANG ZB. A novel predictive model of pathological lymph node metastasis constructed with preoperative independent predictors in patients with renal cell carcinoma. J Clin Med. 2023, 12:441.Search in Google Scholar